Faron, etusivu

releases and publications

Financial Statement January 1 to December 31 2023

Regulatory

Binding commitments for convertible loans

Regulatory

Replacement - Update to 2024 Financial Calendar

Regulatory

Update to Faron’s Financial Calendar for 2024

Regulatory

Continued Negotiations Regarding Events of Default

Regulatory

Events of Default

Regulatory

Further re: Exercise of options

Regulatory

BEXMAB Insights into Patient Profiles

Regulatory

Exercise of options

Regulatory

Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial

Regulatory
PreviousNext
Back to top